Portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced an update to its clinical development strategy and reported its financial results for the year ended December 31, 2023.
Extracts of the announcement are below.
- Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial
- As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC, PDS0101 (Versamune® HPV) and KEYTRUDA® in advanced head and neck cancer
- Strong safety profile of IL-12 fused antibody drug conjugate (PDS01ADC) demonstrated to date with data generated in >300 cancer patients; Versamune® HPV tested in >110 HNSCC patients
- Successful recent meeting with FDA provided clear guidance on trial design and regulatory pathway for pivotal randomised trial of triple combination in recurrent metastatic HPV-positive HNSCC
Read more here.